Rheumatology – Page 2

UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study

By MedXY 12/04/2025

The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA achievers), and may improve objective monitoring of PsA.

news Rheumatology

Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up

By MedXY 12/03/2025

Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to higher urate and residual crystal burden.

news Orthopedics Rheumatology

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective

By MedXY 12/01/2025

The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-effectiveness in favour of PKR.

news Rheumatology

Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy

By MedXY 12/01/2025

The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were similar for both strategies.

Dermatology news Rheumatology

Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions

By MedXY 12/01/2025

A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimination was good (C≈0.8).

AI news Rheumatology

Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern

By MedXY 12/01/2025

A multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is needed.

Cardiology news Rheumatology

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

By MedXY 11/30/2025

A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among those with primary APS.

news Rheumatology

FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results

By MedXY 11/27/2025

In DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to placebo.

Dermatology news Rheumatology

Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial

By MedXY 11/12/2025

A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable short‑term safety profile.

$Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach$

Hematology-Oncology news Rheumatology

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY 11/12/2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and plasma‑cell clones.

news Orthopedics Rheumatology

Intra-articular Hyaluronic Acid Injections: Long-Term Benefits in Early-Stage Knee Osteoarthritis and Older Women

By MedXY 11/04/2025

Systematic review of 71 RCTs reveals that intra-articular hyaluronic acid injections offer initial symptom worsening but significant long-term relief, especially in early-stage knee osteoarthritis and older women; molecular weight’s role requires further study.

news Rheumatology

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease

By MedXY 11/04/2025

Single-cell and spatial multi-omics reveal loss of a PRR4⁺CST3⁺ seromucous acinar population and accumulation of GZMK⁺CD8⁺ T cells that induce IFN-driven epithelial dysfunction in Sjögren’s disease.

Neurology news Rheumatology

Outcomes of Maintenance Immunotherapy in Susac Syndrome

By MedXY 11/02/2025

This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.

news Orthopedics Rheumatology

Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms

By MedXY 11/02/2025

Partitioning a knee osteoarthritis polygenic score into BMI-associated and BMI-independent components clarifies genetic contributions, improves interpretability, and offers a path to tailored prediction and prevention.

news Orthopedics Rheumatology

Targeting Modifiable Risks to Prevent Knee Osteoarthritis

By MedXY 11/01/2025

A large systematic review identified prior knee injury, older age, and high bone mineral density as predictors of incident radiographic knee osteoarthritis; overweight/obesity and prior injury explained ~14% of cases—highlighting prevention priorities across the life course.

news Orthopedics Rheumatology

Physical Activity and Risk of Knee Replacement in Radiographic Osteoarthritis

By MedXY 11/01/2025

In a 9-year OAI cohort analysis, baseline self-reported moderate physical activity was linked to lower knee replacement risk in KL grade 2 but to higher risk in KL >2; high activity showed no clear effect. Results support severity-tailored activity advice and highlight limitations of single self-report measures.

news Orthopedics Rheumatology

Baseline Sarcopenia Predicts Faster Knee Osteoarthritis Progression and Much Higher Risk of Knee Replacement

By MedXY 11/01/2025

In a longitudinal analysis of 4,316 Osteoarthritis Initiative participants, baseline sarcopenia screened by SARC-F and chair-stand testing was associated with accelerated radiographic and symptomatic knee OA progression over 24–48 months and substantially higher risk of subsequent knee replacement.

news Orthopedics Rheumatology

Chondrocalcinosis Predicts Incident Knee Osteoarthritis

By MedXY 11/01/2025

Two large longitudinal cohorts show baseline chondrocalcinosis is associated with ~75% higher odds of developing radiographic knee osteoarthritis over long-term follow-up, suggesting calcium crystal deposition may be a contributing factor in OA pathogenesis.

Diabetes & Endocrinology news Rheumatology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

By MedXY 10/31/2025

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential immunomodulatory benefits of SGLT-2 inhibitors beyond glycemic control.